Keratosis Lichenoides Chronica: Treatment with Bath-PUVA

Christian Kunte¹, Karin Kerschenlohr¹, Martin Röcken¹² and Carl Georg Schirren¹³

Department of Dermatology, ¹Ludwig-Maximilians University of Munich, Frauenlobstraße 9–11, DE-80337 München, ²Eberhard Karls University of Tübingen, and ³Dermatohistopathology Institute, Darmstadt, Germany. E-mail: C.Kunte@lrz.uni-muenchen.de

Accepted October 26, 2006.

Sir,

Keratosis lichenoides chronica (KLC) is a rare and chronic skin disease characterized by erythemas, keratotic and lichenoid papules, arranged in a linear pattern (1) and seborrhoeic-like scaling lesions on the trunk and limbs (1, 2). The lesions are slowly progressive with no tendency to heal and are resistant to most therapeutic modalities. Typical locations are the limbs, face, nails, palms, soles and mucous membranes (2, 3). No preference has been described for sex or age. Since 1972 the term “keratosis lichenoides chronica”, suggested by Margolis, has been generally accepted for this condition, except in France, where it is named “lichenoid tri-keratosis” (1). KLC is commonly considered either as a distinct entity or as a rare manifestation of lichen planus.

Here we describe 2 young adults with typical clinical features of KLC and propose bath-psoralen plus ultraviolet light A (bath-PUVA) therapy as a potentially useful treatment for this rare disease, which is resistant to most classical anti-inflammatory therapies.

CASE REPORTS

Patient 1

A 27-year-old, otherwise healthy man suffered for 5 years from slightly itchy papules of the limbs and genital area. The patient had not received any tuberculostatic therapy.

The flexural areas of the limbs showed violaceous, papular and partially keratotic lesions arranged in a linear pattern (Fig. 1). The pubic region was affected by densely aggregated erythematous lichenoid and partially keratotic papules and plaque-like keratitis. Scattered papules were also found on the trunk. The face, palms, soles and nails were unaffected.

A skin biopsy revealed irregular acanthosis with loss of the granular layer and compact parakeratosis, overlying a band-like infiltrate of lymphocytes and histiocytes in the upper dermis. The basal layer showed vacuolar alteration, colloid bodies and dyskeratotic cells (Fig. 2).

Direct immunofluorescence investigations showed deposition of fibrinogen in a diffuse pattern along the dermo-epidermal junction.

Complete blood count, hepatitis and HIV serology, Treponema pallidum haemagglutination assay (TPHA) and Venereal Diseases Research Laboratory (VDRL) test and antinuclear antibodies were normal. IgG antibodies against toxoplasmosis were positive.

During bath-PUVA therapy (body: 75 treatments for 14 months with a total dose of 117 J/cm²; knees and elbows: 25 treatments for 4 months with a total dose of 79.5 J/cm²) did not improve the disease.

DISCUSSION

Histological examination of KLC reveals lichenoid dermatitis with hyper- and parakeratosis, loss of the granular layer, a band-like inflammatory subepidermal infiltrate and colloid bodies (4). Although the aetiology
and pathogenesis of KLC are unknown, its close similarity to lichenoid drug eruption induced by tuberculostatic and anti-malarial drugs suggest that KLC is a variant of lichenoid drug eruptions (1). Menter & Morrison (5) described 3 cases of KLC, suggesting that it might be a cutaneous manifestation of toxoplasmosis.

Therapy with keratolytic agents, tar or glucocorticoids is usually ineffective. Successful treatment has been reported with oral PUVA, bath-PUVA, aromatic retinoids and topical calcipotriol (6–14).

Since lichen planus responds favourably to bath-PUVA therapy, and since bath-PUVA therapy also seems to be superior to oral PUVA in the treatment of lichen planus, we initiated bath-PUVA therapy in the 2 patients with KLC. Beneficial effects of oral photochemotherapy were reported in 2 patients with KLC (11, 14), and a partial response in a third case (12). One patient cleared completely with bath-PUVA alone.

It is well known that UVA irradiation, especially in combination with 8-methoxy-psoralen, has profound immunomodulatory effects. One possible mechanism may be the inactivation of dendritic cells caused by suppressing the interaction between specialized antigen-presenting cells and lymphocytes. This may lead to reduced production of cytokines, such as IL2 and γ-interferon, upregulation of IL4, and induction of IL3, IL6 and tumour necrosis factor. However, the exact mode of action of bath-PUVA therapy remains unknown.

REFERENCES